Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Brl Medicine (Shanghai) Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's prosecution is currently concentrated under 1 distinct examiner and 1 distinct art unit, indicating a focused effort on a specific medical or biological innovation. This streamlined approach allows for a clear and direct communication channel with the patent office. The presence of 1 pending office action in 1 distinct art unit suggests that the company is prioritizing a core pharmaceutical technology at this stage.
LEITH, NANCY J is the busiest examiner, with 1 busiest examiner pending action currently under review. As this 1 action is the only one pending for the company, the examiner's interpretation of the claims will be the primary factor in the portfolio's immediate growth. The involvement of 1 distinct art unit means the company is not currently managing the complexities of different examination styles across multiple biotech groups. This allows the company to focus all its resources on resolving the 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEITH, NANCY J | 1 | 74.7% | +44.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025136 | METHOD FOR PERFORMING GENE EDITING ON TARGET SITE IN CELL | LEITH, NANCY J | 9d overdue |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18025136 | METHOD FOR PERFORMING GENE EDITING ON TARGET SITE IN CELL | LEITH, NANCY J | 1636 | §102 | Final Rejection | 9d overdue | Pending | Mar 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial